IN8bio released FY2025 Semi-Annual earnings on August 7, 2025 (EST) with actual revenue of USD 0 and EPS of USD -3.645

Brief Summary

IN8bio reported its 2025 fiscal half-year earnings on August 7, showing a revenue of $0 and an EPS of -3.645 USD per share, highlighting a significant financial loss.

Impact of The News

IN8bio Inc., a clinical-stage biotechnology company focused on developing gamma-delta T cell therapies for cancer and autoimmune diseases, released its financial results for the second quarter of 2025 on August 7th. The company reported a revenue of $0 and an earnings per share (EPS) of -3.645 USD. This performance is below market expectations and reflects a substantial loss for the company in this period Motley Fool. The lack of revenue aligns with prior market forecasts which indicated no expected change in quarterly income for IN8bio for the quarter ending June 30, 2025 Reuters.

The significant loss and absence of revenue suggest that IN8bio’s ongoing clinical trials and developmental phases have not yet yielded commercial products or generated income from partnerships or licensing deals. Compared to other biotechnology companies, IN8bio’s financial performance is notably poor. For instance, ARM Holdings reported a quarterly revenue of 10.53 billion USD with a year-over-year growth of 12.1% , whereas AMD achieved a revenue of 7.69 billion USD with a growth of 31.7% in the same quarter . This highlights the challenging financial position IN8bio is currently facing.

Moving forward, if IN8bio can achieve positive results in its clinical trials and secure regulatory approvals, there is potential for future revenue generation. However, the current financial situation indicates that the company may need additional funding or strategic partnerships to sustain its operations and continue its research and development activities.